Risk factors associated with bloodstream infections among critically ill patients with COVID-19. Issue 5 (November 2021)

• Record Type: Journal Article
• Authors: McMillan, Tim; Jones, Conor; O'Connor, Cavan J; Nolan, Daniel; Chan, Xin Hui S; Ellis, Jayne; Thakker, Clare; Kranzer, Katharina; Stone, Neil RH; Singer, Mervyn; Wilson, A Peter R; Arulkumaran, Nishkantha
• Is Part Of: Journal of infection. Volume 83:Issue 5(2021)
• Page Start: e1
• Page End: e3
• Publication Date: 2021-11
• Subjects: Covid-19 -- Bloodstream infection -- Corticosteroid -- Tocilizumab; Infection -- Periodicals; Bacterial Infections -- Periodicals; Communicable Diseases -- Periodicals; Electronic journals; 616.905
• DOI: 10.1016/j.jinf.2021.09.010
• Languages: English
• ISSNs: 0163-4453

Abstract

Highlights: Approximately one in five critically ill patients with COVID-19 develop a bloodstream infection (BSI). The median time from hospital admission to developing a BSI was 18 days. Tocilizumab and dexamethasone are not associated with increased risk of BSI.